The copper peptide that resets aging skin
Injection, Topical · 503A Compounding
Educational content. This page describes GHK-Cu for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide bound to a copper(II) ion. It was first isolated from human plasma by Loren Pickart, who reported in the late 1970s and 1980 that this small peptide associates tightly with copper and iron and influences the growth and survival of cultured cells. The peptide is also present in saliva and urine, and a GHK sequence sits within the alpha-2 chain of type I collagen, which means injured tissue can release it locally as collagen breaks down.
GHK circulates at meaningful levels in young adults and declines with age, a drop that parallels the slowing of tissue repair seen in older skin and other organs. That age-related fall, combined with copper's role as a cofactor for matrix-building enzymes, is the rationale behind using GHK-Cu in topical anti-aging formulas and, more experimentally, as an injectable. It has been studied for more than four decades, though the bulk of that work is laboratory and animal research rather than large human trials.
GHK-Cu delivers copper to cells in a chelated form. Carrying the ion this way limits the free-radical chemistry that loose copper can trigger while still making it available as a cofactor for enzymes such as lysyl oxidase and superoxide dismutase, which the body needs to crosslink collagen and neutralize oxidative stress.
At the tissue level, the peptide signals dermal fibroblasts to produce collagen, elastin, and glycosaminoglycans including dermatan sulfate and the proteoglycan decorin, while balancing matrix metalloproteinases against their inhibitors so that remodeling stays organized rather than destructive. This dual build-and-remodel action is documented in fibroblast cultures and in animal wound models.
The most striking proposed mechanism is transcriptional. Using public gene-expression databases, Pickart and Margolina reported that GHK shifts expression of about 31% of human genes, upregulating DNA repair genes, suppressing pro-inflammatory NF-kappaB signaling, and activating the proteasome system that clears damaged proteins. These are bioinformatic and cell-level findings, not outcomes from human trials.
The copper peptide that resets aging skin
GHK-Cu acts on two levels at once. It ferries copper as a safe enzymatic cofactor and directly signals fibroblasts to rebuild collagen, elastin, and glycosaminoglycans, while at the genetic level it shifts expression of a large fraction of the human genome toward repair, upregulating DNA repair genes, calming NF-kappaB-driven inflammation, and activating the proteasome that clears damaged proteins.
GHK-Cu stimulated collagen synthesis beginning near 1 picomolar and peaking around 1 nanomolar, independent of any change in cell number, establishing the peptide as a direct signal for matrix production.
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP · FEBS Lett, 238(2):343-6 (1988) · PubMed
GHK-Cu produced dose-dependent increases in collagen, glycosaminoglycans, and DNA in healing tissue, with collagen accumulation outpacing non-collagen protein, confirming the culture findings in living tissue.
Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, et al. · J Clin Invest, 92(5):2368-76 (1993) · PubMed
At 1 nanomolar, GHK-Cu restored proliferation of radiation-damaged fibroblasts toward normal and raised secretion of VEGF and bFGF, suggesting a route to rescuing repair capacity in damaged tissue.
Pollard JD, Quan S, Kang T, Koch RJ · Arch Facial Plast Surg, 7(1):27-31 (2005) · PubMed
GHK-Cu lowered reactive oxygen species, raised superoxide dismutase, and reduced TNF-alpha and IL-6, attenuating inflammation through suppression of NF-kappaB signaling.
Park JR, Lee H, Kim SI, Yang SR · Oncotarget, 7(36):58405-58417 (2016) · PubMed
start low, go slow
Topical (serum or cream)
Subcutaneous injection
Topical (serum or cream): The most studied and most accessible route. Improvements are gradual and structural.
Subcutaneous injection: Far less studied than topical use; human data for the injectable form are limited.
Dosing is determined by a licensed provider based on your goals, the formulation, and whether the topical or injectable route is being used. Concentrations vary widely between cosmetic and compounded products.
Topical benefits develop over roughly 8 to 12 weeks because they reflect new collagen and matrix being laid down rather than a surface effect, so consistency matters more than dose escalation.
Layering topical GHK-Cu in the same routine as strong vitamin C, alpha hydroxy acids, or retinoids can blunt the copper complex or increase irritation. Many users separate them to different times of day.
Topical GHK-Cu has a long record of cosmetic use and is generally well tolerated, with irritation being the main complaint. It is not an FDA-approved drug.
Safety of the injectable form is much less established. The FDA has flagged injectable GHK-Cu over immunogenicity and impurity concerns, so systemic use should be supervised by a provider who can monitor for adverse effects.
Because the complex delivers copper, anyone with a copper-handling disorder should avoid it. Wilson's disease is an absolute contraindication, and people with significant liver disease or hemochromatosis should not use GHK-Cu.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| GHK-Cu | Anti-Aging & Skin Regeneration | Topical, Injection | 8-12 weeks | A naturally occurring copper-carrier peptide that rebuilds the skin matrix and, per gene-expression analysis, shifts expression of about a third of human genes toward repair |
| SS-31 (Elamipretide) | Mitochondrial restoration and rare mitochondrial disease | Subcutaneous injection (daily); IV in trials | Ongoing daily dosing | The first FDA-approved mitochondria-targeted therapeutic; binds cardiolipin on the inner mitochondrial membrane to support electron transport efficiency |
| Sermorelin | GH restoration and healthy aging | Subcutaneous injection, daily at bedtime | 3-6 months | The GHRH analog with prior FDA approval and a multi-decade clinical record, preserving natural feedback rather than replacing growth hormone |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual, Topical | Ongoing supplementation | The body's own master antioxidant, with controlled human data showing oral and sublingual forms can raise body stores and immune markers |
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Unusually stable in gastric acid; broad multi-system healing signal, though evidence is largely preclinical |
This substance is in Category 1 of the FDA's 503A bulk drug substances evaluation. Licensed 503A pharmacies may compound it under FDA enforcement discretion while the agency continues its review.
Only the injectable form is pending reclassification. Topical GHK-Cu is already in Category 1 and compoundable today.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Split status: topical GHK-Cu is in Category 1 and licensed 503A pharmacies may compound it under FDA enforcement discretion. Injectable GHK-Cu is in Category 2 due to immunogenicity and impurity concerns; 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it.
Listed as Category 1 for non-injectable routes; Category 2 for injectable routes of administration
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into GHK-Cu? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA mitochondria-targeted tetrapeptide that stabilizes cardiolipin to support cellular energy.
FDA-approved as Forzinity for Barth syndrome in 2025; the first mitochondria-targeted therapeutic approved.
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Formerly marketed as Geref for pediatric GH deficiency; discontinued in 2008 for commercial reasons.
A tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.
“Specializing in Aesthetics and Wellness ”
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering GHK-Cu.